Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1856-1857
DOI: 10.2967/jnumed.126.273360 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.09.2026. Verfasst von Kemal C Gogebakan und 5 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
REPLY: We thank Flannery et al. and Subramanian and Osborne for their thoughtful letters regarding our cost-effectiveness analysis of 177Lu-PSMA-617 versus cabazitaxel ([1][1]). Both letters note the uncertainty surrounding U.S. costs for 177Lu-PSMA-617 therapy. As stated in our article, directly
Zitieren
APA
Gogebakan, K. C., Kunst, N., Ghodsi, A., Owens, L., Iravani, A., & Etzioni, R. (2026). Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”. Journal of Nuclear Medicine, 67(11), 1856-1857. https://doi.org/10.2967/jnumed.126.273360
Vancouver
Gogebakan KC, Kunst N, Ghodsi A, Owens L, Iravani A, Etzioni R. Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”. Journal of Nuclear Medicine. 2026;67(11):1856-1857. doi:10.2967/jnumed.126.273360
BibTeX
@article{Gogebakan2026,
author = {Gogebakan, Kemal C and Kunst, Natalia and Ghodsi, Alireza and Owens, Lukas and Iravani, Amir and Etzioni, Ruth},
title = {Reply to “Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses”},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1856--1857},
doi = {10.2967/jnumed.126.273360}
}
EUVIMED